Swasono R. Tamat
Pusat Pengembangan Radioisotop dan Radiofarmaka, BATAN, Serpong.

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

Pengaruh Ekstrak Etanol Daun Murbei (Morus Alba L.) dengan Glibenklamid Terhadap Ekspresi Gen CYP3A4 pada Kultur Sel HepG2 Nuralih, Nuralih; Churiyah, Churiyah; Pambudi, Sabar; Tamat, Swasono R.; Meila, Okpri
Pharmacon: Jurnal Farmasi Indonesia Vol 15, No 1 (2018)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v15i1.5766

Abstract

Mulberry leaf is a traditional herb and predicted has ecdysteronecompound which act as antihyperglicemid. Glybenclamide is a synthetic medicine used to cure diabetes mellitus type 2. The leaf reported as competitive inhibitor of CYP3A4 enzyme, which metabolizingglibenclamide. However, in many cases, combination of herbs with synthesis drugs causes interaction if used at the same time. This research aimed to see interaction of ethanol mulberry leaf extract with glibenclamide through CYP3A4 gene expression in HepG2 cell culture.Sample of mulberry extract, glibenclamide, and combination both sample were tested into cell HepG2 culture. Then RNA were isolated and purification using real time PCR to see the gene CYP3A4 expression. As a result, mulberry extract acts as inhibitor enzyme CYP3A4, while glibenclamide is enzyme substrate.The combination of mulberry and glibenclamide showed increased of expression of CYP3A4 gene, means greater enzyme produced, and lower medicine on blood plasma.
RADIOISOTOPES AND RADIOPHARMACEUTICALS IN NUCLEAR CARDIOLOGY Tamat, Swasono R.
Jurnal Radioisotop dan Radiofarmaka Vol 4, No 1,2 (2001): JURNAL PRR 2001
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (6982.246 KB)

Abstract

RADIOISOTOPES AND RADIOPHARMACEUTICALS IN NUCLEAR CARDIOLOGY. Nuclear medicine studies of the heart represent one of the fastest growing areas of research and clinical interest. Some years ago, nuclear medicine cardiac studies were limited to evaluations of myocardial infarction. Developments in radiopharmaceutical chemistry and instrumentation have made possible advances in cardiovascular nuclear medicine. Techniques and radiopharmaceuticals now exist for the imaging of viable myocardium and the determination of myocardial tissue metabolism, as well as radionuclide angiography to obtain quantitative information of cardiac output, mean transit times, cardiac volumes, and ejection fractions. This paper will firstly describe the anatomy and physiology of the heart as to relate to the radiopharmaceuticals which will be discussed, and will secondly explore various radiopharmaceuticals which have been used for various purposes in cardiac imaging, then will explore radioisotopes which have been proposed for myocardial treatment. RADIOISOTOP DAN RADIOFARMAKA DI BIDANG KARDIOLOGI NUKLIR. Studi jantung secara kedokteran nuklir merupakan salah satu bidang penyidikan dan minat klinis yang paling cepat berkembang. Beberapa tahun lalu, studi jantung secara kedokteran nuklir terbatas pada evaluasi infark jantung. Perkembangan di bidang kimia-radiofarmaka dan instrumentasi telah mendorong kemajuan di bidang kedokteran nuklir kardiovaskular. Teknik-teknik dan radiofarmaka sekarang telah tersedia untuk penyidikan jaringan jantung yang masih hidup dan penentuan metabolisme jaringan jantung, dan juga angiografi radionuklida untuk memperoleh informasi kuantitatif mengenai luaran jantung, waktu transit rata­ rata, volume jantung, dan fraksi ejeksi. Makalah ini pertama akan menerangkan anatomi dan fisiologi jantung dalam kaitannya dengan radiofarmaka yang akan dibahas, dan kemudian akan meninjau berbagai radiofarmaka yang telah digunakan untuk berbagai keperluan penyidikan jantung, dan kemudian meninjau radioisotop yang telah diusulkan untuk penanganan masalah jantung.
SINTESIS DAN KARAKTERISASI MEBROFENIN UNTUK PENYIDIK SISTEM HEPATOBILIARI Purwoko, Purwoko; Tamat, Swasono R.; Yunita, Fitri; Kristanti, Eti
Jurnal Radioisotop dan Radiofarmaka Vol 6, No 2 (2003): Jurnal PRR 2003
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (2818.392 KB)

Abstract

ABSTRAKSINTESIS DAN KARAKTERISASI MEBROFENIN UNTUK PENYIDIK SISTEM HEPATOBILIARI Mebrofenin bertanda Teknisium-99m adalah sediaan radiofrmaka yang mempunyai sifat ideal dan unggul untuk penyidikan dan uji fungsi hati dan empedu. Telah dilakukan penelitian sintesis dan karakterisasi  Mebrofenin (3-bromo-2,4,6- trimetil asetanilida iminodiasetat), yang merupakan senyawa turunan IDA, melalui tiga tahap reaksi yaitu etilasi senyawa 2,4,6 trimetil anilin untuk mendapatkan senyawa 2,4,6-trimetil khloro asetanilida, dilanjutkan brominasi sehingga diperoleh senyawa turunan bromotrimetil dan reaksi substitusi nukleofilik dengan asam Iminodiasetat (IDA) untuk menghasilkan mebrofenin. Reaksi asetilasi dan brominasi dilakukan dalam suasana asam asetat sedangkan reaksi substitusi dilakukan dengan cara refluks selama 5 jam dalam pelarut etanol dan air dengan pH 11. Pelarut etanol diuapkan melalui destilasi tekanan rendah, sisa larutan campuran kemudian disaring. Larutan filtrate dikondisikan menjadi pH 2-2,5 dan endapan mebrofenin yang diperoleh direkristalisasi 3 kali dengan etanol. Karakterisasi  terhadap mebrofenin dilakukan dengan pengamatan titik leleh (197-199°C), analisis spectrum ultra ungu, spektrum infra merah, spektrum ultra ungu, spectrum infra masa  dan kromatografi cair - HPLC. Hasil karakterisasi menunjukkan bahwa sintesis menghasilkan mebrofenin dengan kemumian tinggi dan dengan rendemen20%. ABSTRACT SYNTHESIS AND CHARACTERIZA ION OF MEBROFENIN FOR HEPATOBILLIARY IMAGING. Mebrofenin labeled with Technet um-99m is a new radiophannaceutical having superior and ideal characteristic as a hepatobilliary-imaging gent. The synthesis and characterization of Mebrofenin (3Bromo-2,4,6-trimethyl acetanilido imminodiac ic acid) as IDA derivative has been carried out involvingthree steps of reaction i.e. : acetyllization of 2,4 6-Trimethyl aniline to get 2,4,6-trimethyl chloro acetanilidewhich upon bromination gives the intermedi te bromotrimethyl derivative and fmally by nucleo phylicsubstitution this intermediate product with' nodiacetic acid (IDA) gives mebrofenin. The acetylation and bromination reactions were carried out in acetic acid condition while the substitution was carried out byreflux for 5 hours in ethanol and water adjusted it pH 11.  The ethanol was then removed under low pressure,and the unreacted compound was removed by tltration. The filtrate was adjusted to pH 2 - 2.5, and theresulting mebrofenin was isolated by filtration nd recrystallized 3 times in ethanol. Characterization of themebrofenin product was performed by observi g its melting point (l97-1990C), ultra violet and infra redspectra as well as mass spectrometric and high performance liquid chromatographic analysis. The results showed that the product was highly pure and the yield was around 20 %.  
Preparasi dan Uji Biodistribusi Sediaan 153Sm--Mikrosfer Albumin Untuk Senovektomi Radiasi Widjaksana, Widyastuti; Tamat, Swasono R.; Sardjoko, Sardjoko; Indrawati, Teti; Fatimah, Fatimah; Auliya, Anna
Jurnal Radioisotop dan Radiofarmaka Vol 6, No 1 (2003): Jurnal PRR 2003
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (11889.697 KB)

Abstract

PREPARASI DAN UJI BIODISTRmUSI SEDIAANS
PENGUJIAN IN-VITRO PENGIKATAN SENYAWA Sm-153 EDTMP PADA KOMPONEN DARAH Dj., Sukiyati; Tamat, Swasono R.; Faisal, Fitra Welly
Jurnal Radioisotop dan Radiofarmaka Vol 2, No 1/2 (1999): JURNAL PRR 1999
Publisher : Jurnal Radioisotop dan Radiofarmaka

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (3066.357 KB)

Abstract

PENGUJIAN IN-VITRO PENGIKATAN SENYAWA 153Sm-EDTMP PADA KOMPONEN DARAH. 153Sm-EDTMP telah digunakan untuk: diagnosis dan terapi kanker tulang metastasis. Biodistribusi senyawa tersebut pada hewan dan uji pre-klinik pada pasien telah banyak dilaporkan, namun masih sedikit pengujian pengikatan biokimia senyawa tersebut yang dilaporkan. Penelitian ini melaporkan pengujian in-vitro pengikatan biokimia 153Sm-EDTMP pada komponen darah. Pengujian dengan darah total menunjukkan bahwa 12-15% 153Sm-EDTMP terikat pada sel-sel darah, dan sisanya pada komponen plasma darah. Inkubasi dengan suspensi sel darah merah menunjukkan 20% senyawa terikat pada sel darah merah. Ikatan dengan komponen darah terjadi dalam beberapa menit dan stabil in-vitro selama beberapa jam. Pengujian in-vitro dengan plasma darah atau serum menunjukkan bahwa 45-47% senyawa berikatan dengan protein plasma. Perpanjangan waktu inkubasi dengan komponen darah tidak meningkatkan jumlah 153Sm-EDTMP yang terikat, namun senyawa 153Sm-EDTMP yang telah terikat pada komponen darah akan segera terlepas bila berada di lingkungan kristal hidroksiapatit dan terikat pada kristal tersebut. IN-VITRO INVESTIGATION OF 153Sm-EDTMP BINDING ON BLOOD COMPONENTS. 153Sm-EDTMP are well known for diagnosis and therapy of bone cancer metastasis. Biodistribution in animals and pre-clinical trials of the compound in patients have often been reported. However, very little investigation on the biochemical binding of the compound has been reported. The present paper reported in­ vitro investigation on the biochemical binding of 153Sm-EDTMP to blood components. Investigation with whole blood showed that 12-15% of 153Sm-EDTMP bound to the blood cells. A similar 20% binding has been shown when the compound was incubated with sedimented red cells. The binding was within minutes and stable for few hours in-vitro. In-vitro investigation with blood plasma or serum showed that 45-47% of the compound bound to the plasma proteins. Extended incubation with the blood components did not increase the 153Sm-EDTMP binding, however, 153Sm-EDTMP bound to the blood components were immediately released when present in the vicinity of hydroxyapatite crystals and bound to the crystals.
PENGARUH PENAMBAHAN URASIL DALAM MEDIA FERMENTASI TERHADAP HASIL β-GLUKAN DARI DUA GALUR AGROBACTERIUM Kusmiati, Kusmiati; Tamat, Swasono R.; Nuswantara, Sukma; Muhamad, Salmah
Makara Journal of Science Vol. 11, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Influence of Uracil in Fermentation Media on β-Glucan Production by Agrobacterium Radiobacter A 1.5 and Agrobacterium sp. Bro 1.2.1. Optimum β-glucan production can be achieved by an optimum condition in the fermentation media. Uracil, as a precursor of UDP-glucose, may act as a glucose donor in the formation of polysaccharides such as β-glucan. It is expected that addition of certain quantity of uracil into the fermentation media in a suitable growth phase of Agrobacterium radiobacter A 1.5 and Agrobacterium sp. Bro 1.2.1, will significantly increase the β-glucan production. In this investigation, 0.025%; 0.05% or 0.1% of uracil were added into the fermentation media during the logarithmic phase (24 hour) or stationary phase (46 hour) of growth. The β-glucan product was evaluated from the β-glucan (crude) dry-weight and from the β-glucan content. Beta-glucan content was determined as glucose by the Hisamatsu-AOAC and HPLC methods. The highest β-glucan (crude) dry-weight produced by the A. 1.5 was in a medium containg 0.025% uracil (24 hour), whilst by the A. Bro 1.2.1 was in a medium containg 0.1% uracil (46 hour), both higher than control. The highest β-glucan content produced by the A. 1.5 (27.03%) was in a medium containg 0.025% uracil (46 hour), while control produced only 23.28%. The highest β-glucan content produced by the Bro 1.2.1 (29.34%) was in a medium containg 0.025% uracil (24 hour), while control produced only 28.75%. Two-way anova analysis showed that there were no significant influence difference (α = 0,05) from various concentration of uracil in either growth phases, to the yield of β-glucan (crude) dry-weight nor to the β-glucan equivalent glucose content.